Dangers in the use of systemic and local drugs expressed in eye disorders – a literature review
DOI:
https://doi.org/10.12775/QS.2024.18.53337Keywords
drug-induced dry eye disease, drug-induced cataract, drug-induced glaucoma, drug-induced corneal damageAbstract
Introduction and purpose
Medications that have been available for many years are commonly used to treat various illnesses. However, nearly all of them can also have toxic effects on other organs, including the eyes, in addition to their therapeutic benefits. In this review, we discuss chosen drug-induced eye disorders, their specific clinical characteristics, and the mechanisms by which certain drugs can damage the ocular system. Isotretinoin and certain chemotherapy drugs are known to contribute to the development of dry eye syndrome. Atimalarial drugs, amiodarone, nonsteroidal anti-inflammatory drugs and chlorpromazine cause the formation of corneal deposits. Prolonged use of glucocorticoids leads to the development of characteristic posterior subcapsular cataracts. The development of cataracts can also be caused by the use of antipsychotic medications. Paradoxically, drugs used topically to treat glaucoma or other eye diseases may trigger an acute attack of angle-closure glaucoma.
Materials and methods
The methodology for conducting literature search involved utilizing medical subject headings terms to explore PubMed. Search terms included: “drug-induced dry eye disease”, “drug-induced cataract”, “drug-induced glaucoma”, “drug-induced corneal damage”.
Conclusions
Educating patients about the potential ocular side effects of newly introduced treatment is crucial so that they can quickly consult an ophthalmologist if symptoms occur. Adjusting the dosage or discontinuing the drug may alleviate ocular symptoms, but these changes must be considered in light of the overall risk posed by the underlying disease. Every treatment should aim to offer the patient maximum benefits while minimizing any adverse impact on their quality of life.
References
Kam KW, Di Zazzo A, De Gregorio C, Narang P, Jhanji V, Basu S. A review on drug-induced dry eye disease. Indian J Ophthalmol. 2023 Apr;71(4):1263-1269. doi: 10.4103/IJO.IJO_2782_22. PMID: 37026257; PMCID: PMC10276716.
Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications : recognition and management. Drugs. 2007;67(1):75-93. doi: 10.2165/00003495-200767010-00006. PMID: 17209665.
Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31(2):127-41. doi: 10.2165/00002018-200831020-00003. PMID: 18217789.
Drug-induced corneal damage. Prescrire Int. 2014 Apr;23(148):97-100. PMID: 24860895.
Huang R, Su C, Fang L, Lu J, Chen J, Ding Y. Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol. 2022 Oct;42(10):3253-3272. doi: 10.1007/s10792-022-02320-7. Epub 2022 Jun 9. PMID: 35678897; PMCID: PMC9178318.
Rouen PA, White ML. Dry Eye Disease: Prevalence, Assessment, and Management. Home Healthc Now. 2018 Mar/Apr;36(2):74-83. doi: 10.1097/NHH.0000000000000652. PMID: 29498987.
Tanriverdi C, Nurozler Tabakci B, Donmez S. Longitudinal assessment of meibomian glands and tear film layer in systemic isotretinoin treatment. Eur J Ophthalmol. 2021 May 20:11206721211018361. doi: 10.1177/11206721211018361. Epub ahead of print. PMID: 34011178.
Caglar C, Senel E, Sabancilar E, Durmus M. Reduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment. Int Ophthalmol. 2017 Feb;37(1):197-202. doi: 10.1007/s10792-016-0263-y. Epub 2016 May 18. PMID: 27193123.
Düzgün E, Özkur E. The effect of oral isotretinoin therapy on meibomian gland morphology and dry eye tests. J Dermatolog Treat. 2022 Mar;33(2):762-768. doi: 10.1080/09546634.2020.1774041. Epub 2020 Jun 8. PMID: 32506981.
Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of taxanes: The Mayo Clinic experience. Eur J Ophthalmol. 2022 Jan;32(1):602-611. doi: 10.1177/1120672120969045. Epub 2020 Nov 4. PMID: 33148049.
Turaka K, Nottage JM, Hammersmith KM, Nagra PK, Rapuano CJ. Dry eye syndrome in aromatase inhibitor users. Clin Exp Ophthalmol. 2013 Apr;41(3):239-43. doi: 10.1111/j.1442-9071.2012.02865.x. Epub 2012 Nov 6. PMID: 22957932.
Khoo P, Groeneveld T, Boyle F, O'Neill S, Forster B, Watson SL. Dry eye signs and symptoms in patients on aromatase inhibitor therapy. Eye (Lond). 2022 Apr;36(4):766-772. doi: 10.1038/s41433-021-01538-6. Epub 2021 Apr 19. PMID: 33875824; PMCID: PMC8956617.
Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, Ulrich RG. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017 May-Jun;62(3):286-301. doi: 10.1016/j.survophthal.2016.11.008. Epub 2016 Nov 24. PMID: 27890620.
Sahyoun JY, Sabeti S, Robert MC. Drug-induced corneal deposits: an up-to-date review. BMJ Open Ophthalmol. 2022 Mar 25;7(1):e000943. doi: 10.1136/bmjophth-2021-000943. PMID: 35415268; PMCID: PMC8961126.
Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol. 1990 Aug;25(5):249-51. PMID: 2207871.
Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, Leggat PA, Pickford P, Kerr C, Ohrt C, Prescott W; Tafenoquine Study Team. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother. 2010 Feb;54(2):792-8. doi: 10.1128/AAC.00354-09. Epub 2009 Dec 7. PMID: 19995933; PMCID: PMC2812156.
WETTERHOLM DH, WINTER FC. HISTOPATHOLOGY OF CHLOROQUINE RETINAL TOXICITY. Arch Ophthalmol. 1964 Jan;71:82-7. doi: 10.1001/archopht.1964.00970010098016. PMID: 14066046.
Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol. 1982 Oct;66(10):676-9. doi: 10.1136/bjo.66.10.676. PMID: 7115651; PMCID: PMC1039895.
D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol. 1981 Feb;99(2):257-61. doi: 10.1001/archopht.1981.03930010259007. PMID: 6258544.
Mäntyjärvi M, Tuppurainen K, Ikäheimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 1998 Jan-Feb;42(4):360-6. doi: 10.1016/s0039-6257(97)00118-5. PMID: 9493278.
Fitt A, Dayan M, Gillie RF. Vortex keratopathy associated with ibuprofen therapy. Eye (Lond). 1996;10 ( Pt 1):145-6. doi: 10.1038/eye.1996.30. PMID: 8763326.
Szmyd L Jr, Perry HD. Keratopathy associated with the use of naproxen. Am J Ophthalmol. 1985 May 15;99(5):598. doi: 10.1016/s0002-9394(14)77969-3. PMID: 4003502.
Molina-Ruiz AM, Pulpillo Á, Molina-Ruiz RM, Sagrario T, Requena L. Chlorpromazine-induced severe skin pigmentation and corneal opacities in a patient with schizophrenia. Int J Dermatol. 2016 Aug;55(8):909-12. doi: 10.1111/ijd.13085. Epub 2015 Sep 4. PMID: 26340849.
Huff LS, Prado R, Pederson JF, Dunnick CA, Lucas LM. Chlorpromazine-induced skin pigmentation with corneal and lens opacities. Cutis. 2014 May;93(5):247-50. PMID: 24897137.
Drug-induced cataracts. Prescrire Int. 2011 Feb;20(113):41-3. PMID: 21488590.
Nishigori H. [Steroid (glucocorticoid)-induced cataract]. Yakugaku Zasshi. 2006 Oct;126(10):869-84. Japanese. doi: 10.1248/yakushi.126.869. PMID: 17016018.
Kačmař J, Cholevík D. Corticosteroid Induced Posterior Subcapsular Cataract. Cesk Slov Oftalmol. 2019 Summer;74(6):226-232. English. doi: 10.31348/2018/6/2. PMID: 31238690.
Liu A, Manche EE. Bilateral posterior subcapsular cataracts associated with long-term intranasal steroid use. J Cataract Refract Surg. 2011 Aug;37(8):1555-8. doi: 10.1016/j.jcrs.2011.05.020. PMID: 21782102.
Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009 Apr;116(4):652-7. doi: 10.1016/j.ophtha.2008.12.001. Epub 2009 Feb 25. PMID: 19243828.
Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009 Apr;116(4):652-7. doi: 10.1016/j.ophtha.2008.12.001. Epub 2009 Feb 25. PMID: 19243828.
Gowda GS, Hegde A, Shanbhag V, Narayanaswamy JC, Jaisoorya TS. Kerato-lenticular ocular deposits and visual impairment with prolonged chlorpromazine use: A case series. Asian J Psychiatr. 2017 Feb;25:188-190. doi: 10.1016/j.ajp.2016.11.002. Epub 2016 Nov 11. PMID: 28262147.
Souza VB, Moura Filho FJ, Souza FG, Rocha CF, Furtado FA, Gonçalves TB, Vasconcelos KF. Cataract occurrence in patients treated with antipsychotic drugs. Braz J Psychiatry. 2008 Sep;30(3):222-6. doi: 10.1590/s1516-44462008000300008. PMID: 18833422.
Razeghinejad MR, Pro MJ, Katz LJ. Non-steroidal drug-induced glaucoma. Eye (Lond). 2011 Aug;25(8):971-80. doi: 10.1038/eye.2011.128. Epub 2011 Jun 3. PMID: 21637303; PMCID: PMC3178216.
Quigley HA. Angle-closure glaucoma-simpler answers to complex mechanisms: LXVI Edward Jackson Memorial Lecture. Am J Ophthalmol. 2009 Nov;148(5):657-669.e1. doi: 10.1016/j.ajo.2009.08.009. PMID: 19878757.
Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol. 2007 Mar;18(2):129-33. doi: 10.1097/ICU.0b013e32808738d5. PMID: 17301614.
Yalvac IS, Tamcelik N, Duman S. Acute angle-closure glaucoma associated with latanoprost. Jpn J Ophthalmol. 2003 Sep-Oct;47(5):530-1. doi: 10.1016/s0021-5155(03)00127-8. PMID: 12967875.
Mapstone R. Dilating dangerous pupils. Br J Ophthalmol. 1977 Aug;61(8):517-24. doi: 10.1136/bjo.61.8.517. PMID: 143952; PMCID: PMC1043030.
Pandit RJ, Taylor R. Mydriasis and glaucoma: exploding the myth. A systematic review. Diabet Med. 2000 Oct;17(10):693-9. doi: 10.1046/j.1464-5491.2000.00368.x. PMID: 11110501.
Corridan P, Nightingale S, Mashoudi N, Williams AC. Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm. Br J Ophthalmol. 1990 May;74(5):309-10. doi: 10.1136/bjo.74.5.309. PMID: 2354140; PMCID: PMC1042106.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Paweł Ziemba, Aleksandra Janocha, Aneta Jerzak, Katarzyna Jakubowska
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 37
Number of citations: 0